What SOPHiA GENETICS SA's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 1 |
| Sells | 53 | 130 |
| Total trades | 65 | 152 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 152 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Xu Zhenyu | Chief Scientific Officer | Aug 27 | Disclosed 10b5-1 sale · S | −10,000 | $8.91 | −$89.1K | 556,887 |
| Hibbs Kathy L | Director | Aug 25 | Disclosed 10b5-1 sale · S | −6,250 | $8.68 | −$54.2K | 103,242 |
| Menu Philippe | Chief Medical Officer | Aug 25 | Disclosed 10b5-1 sale · S | −5,000 | $8.68 | −$43.4K | 213,387 |
| Verma Abhimanyu | Chief Technology Officer | Aug 24 | Disclosed 10b5-1 sale · S | −5,000 | $8.80 | −$44K | 172,171 |
| Xu Zhenyu | Chief Scientific Officer | Aug 21 | Disclosed 10b5-1 sale · S | −5,408 | $8.40 | −$45.4K | 566,887 |
| Xu Zhenyu | Chief Scientific Officer | Aug 20 | Disclosed 10b5-1 sale · S | −4,592 | $8.41 | −$38.6K | 572,295 |
| Verma Abhimanyu | Chief Technology Officer | Aug 19 | Disclosed 10b5-1 sale · S | −5,000 | $8.20 | −$41K | 177,171 |
| Xu Zhenyu | Chief Scientific Officer | Aug 19 | Disclosed 10b5-1 sale · S | −10,000 | $7.94 | −$79.4K | 576,887 |
| Valente Manuela | Chief People Officer | Aug 19 | Disclosed 10b5-1 sale · S | −10,000 | $7.94 | −$79.4K | 210,450 |
| Valente Manuela | Chief People Officer | Aug 19 | Exercise / conversion · M | +10,000 | $3.20 | +$32K | 220,450 |
| Xu Zhenyu | Chief Scientific Officer | Aug 13 | Disclosed 10b5-1 sale · S | −4,000 | $7.52 | −$30.1K | 586,887 |
| Menu Philippe | Chief Medical Officer | Aug 12 | Disclosed 10b5-1 sale · S | −5,000 | $7.52 | −$37.6K | 218,387 |
| Camblong Jurgi | Executive Chairman | Aug 10 | Disclosed 10b5-1 sale · S | −8,500 | $7.61 | −$64.7K | 3,444,322 |
| Xu Zhenyu | Chief Scientific Officer | Aug 07 | Disclosed 10b5-1 sale · S | −10,000 | $7.48 | −$74.8K | 590,887 |
| Xu Zhenyu | Chief Scientific Officer | Aug 07 | Disclosed 10b5-1 sale · S | −7,000 | $7.02 | −$49.2K | 600,887 |
| Xu Zhenyu | Chief Scientific Officer | Aug 07 | Exercise / conversion · M | +7,000 | $3.28 | +$23K | 607,887 |
| Camblong Jurgi | Executive Chairman | Aug 07 | Disclosed 10b5-1 sale · S | −20,000 | $7.23 | −$145K | 3,452,822 |
| Verma Abhimanyu | Chief Technology Officer | Aug 07 | Disclosed 10b5-1 sale · S | −5,000 | $7.60 | −$38K | 182,171 |
| Xu Zhenyu | Chief Scientific Officer | Aug 05 | Disclosed 10b5-1 sale · S | −3,000 | $7.00 | −$21K | 600,887 |
| Xu Zhenyu | Chief Scientific Officer | Aug 05 | Exercise / conversion · M | +3,000 | $3.28 | +$9.84K | 603,887 |
Loading...
